Needham & Company LLC Reaffirms “Buy” Rating for Sarepta Therapeutics Inc. (SRPT)
Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a report released on Saturday. They presently have a $81.00 price objective on the stock. Needham & Company LLC’s price target would indicate a potential upside of 39.92% from the stock’s previous close.
Other analysts have also recently issued research reports about the company. Oppenheimer Holdings Inc. lifted their price target on Sarepta Therapeutics from $60.00 to $76.00 in a report on Monday, September 19th. Robert W. Baird restated a “buy” rating on shares of Sarepta Therapeutics in a report on Friday, June 10th. Janney Montgomery Scott upgraded Sarepta Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $30.00 to $65.00 in a report on Monday, September 19th. Piper Jaffray Cos. set a $68.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a report on Tuesday. Finally, Vetr upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating and set a $17.28 price target for the company in a report on Monday, June 20th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Sarepta Therapeutics has an average rating of “Buy” and an average target price of $58.12.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 57.89 on Friday. The company’s 50 day moving average is $40.98 and its 200-day moving average is $25.39. Sarepta Therapeutics has a 1-year low of $8.00 and a 1-year high of $63.73. The stock’s market capitalization is $2.77 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the firm posted ($0.87) earnings per share. Equities analysts anticipate that Sarepta Therapeutics will post ($4.23) earnings per share for the current fiscal year.
In other news, VP Jayant Aphale sold 35,000 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $1,750,000.00. Following the completion of the sale, the vice president now directly owns 21,490 shares in the company, valued at approximately $1,074,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Edward M. Md Kaye sold 24,557 shares of the business’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the completion of the sale, the chief executive officer now owns 76,983 shares of the company’s stock, valued at $2,309,490. The disclosure for this sale can be found here. 10.90% of the stock is owned by company insiders.
Several large investors have recently modified their holdings of SRPT. BNP Paribas Arbitrage SA increased its stake in shares of Sarepta Therapeutics by 114.0% in the third quarter. BNP Paribas Arbitrage SA now owns 3,541 shares of the company’s stock worth $217,000 after buying an additional 1,886 shares during the period. Harbour Capital Advisors LLC purchased a new stake in shares of Sarepta Therapeutics during the second quarter worth $335,000. Schwab Charles Investment Management Inc. increased its stake in shares of Sarepta Therapeutics by 1.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 153,816 shares of the company’s stock worth $2,934,000 after buying an additional 2,766 shares during the period. Stifel Financial Corp increased its stake in shares of Sarepta Therapeutics by 5.4% in the second quarter. Stifel Financial Corp now owns 23,076 shares of the company’s stock worth $441,000 after buying an additional 1,178 shares during the period. Finally, American Century Companies Inc. purchased a new stake in shares of Sarepta Therapeutics during the second quarter worth $651,000. Institutional investors and hedge funds own 65.29% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.